Latanoprost Yonsung

Latanoprost, the active ingredient in Latanoprost Yonsung, is a prostaglandin F2α analog presented as an eye‑drop solution for ocular use. It is employed to lower intra‑ocular pressure in patients with open‑angle glaucoma or ocular hypertension.

GNH USA supplies Latanoprost Yonsung as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet the needs of eye‑care providers across global markets.

Latanoprost is indicated for ocular conditions where reduction of intra‑ocular pressure is required.

Open‑angle glaucoma: lowers intra‑ocular pressure to slow disease progression. Ocular hypertension: reduces eye pressure to prevent development of glaucoma. Secondary open‑angle glaucoma: helps control pressure when other causes are present.

Latanoprost may cause ocular and systemic reactions; reported events are categorized by frequency.

Common Side Effects: - Eye redness: mild conjunctival hyperemia. - Increased eyelash growth: longer, thicker lashes. - Iris darkening: gradual brownish pigmentation. - Eye irritation: transient burning or stinging.

Serious or Rare Side Effects: - Severe eye inflammation: uveitis or iritis requiring medical attention. - Allergic reaction: swelling, rash, or difficulty breathing. - Paradoxical rise in intra‑ocular pressure: unexpected pressure increase. - Corneal edema: swelling of the cornea affecting vision. - Vision loss: sudden decrease in visual acuity.

When prescribing Latanoprost, clinicians should consider several safety and handling points.

Pregnancy: safety not established; avoid unless clearly needed. Breastfeeding: unknown; weigh potential risks and benefits. Concurrent ocular surgery: postpone treatment at least four weeks before and after the procedure. Contact lens wearers: may cause lens discoloration; consider removal during therapy. Store at room temperature: keep in the original container, protect from light and moisture.

Latanoprost can interact with other ophthalmic or systemic agents; interactions are grouped by clinical relevance.

Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory eye drops: may diminish Latanoprost efficacy. - Systemic prostaglandin analogs: additive effect on intra‑ocular pressure.

Moderate Interactions (Monitor Closely): - Carbonic anhydrase inhibitors: increased risk of ocular inflammation. - Beta‑blocker eye drops: potential additive IOP‑lowering effect. - Anticholinergic agents: may affect tear film stability.